Description:

ODM derived from http://clinicaltrials.gov/show/NCT00655252

Link:

http://clinicaltrials.gov/show/NCT00655252

Keywords:
Versions (1) ▾
  1. 12/9/13
Uploaded on:

December 9, 2013

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00655252 Metastatic Renal Cell Cancer

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 18 Years
metastatic renal cancer, intolerant of or failed sunitinib and/or sorafenib
Adequate bone marrow function, liver function, renal function
Adequate birth control
Other protocol-defined inclusion criteria may apply
Exclusion Criteria
Previously received RAD001 or other mTOR inhibitors, known hypersensitivity to rapamycin, chronic systemic treatment with corticosteroids or immunosuppressive agents (prednisone <= 20 mg/day for adrenal insufficiency OK
Topical or inhaled steroids OK)
Active bleeding
Uncontrolled angina, CHF, heart attack <= 6 months, uncontrolled diabetes
Other protocol-defined exclusion criteria may apply